Safe Pro Group (NASDAQ: SPAI) announced the appointment of Brian Mack, a former Anduril senior business development director and retired U.S. Army acquisition officer, to its Strategic Advisory Board as the company advances growth in AI-enabled defense solutions. Mack brings deep expertise in defense capture and Army modernization, including support for a $100 million U.S. […]

MindWave Innovations (NYSE American: APUS) is a digital asset and technology company providing institutional-grade treasury infrastructure for the digital asset economy. The company offers a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies, and transparent reporting systems. MindWave is focused on supporting corporations and institutional counterparties in holding, managing, and generating […]

ParaZero Technologies (NASDAQ: PRZO) announced the closing of its previously announced registered direct offering with a single institutional investor, generating approximately $4 million in gross proceeds through the sale of 5,333,333 ordinary shares and pre-funded warrants at $0.75 per share. The transaction, which closed March 24, 2026, will support general corporate purposes and working capital, with Aegis Capital Corp. […]

Rail Vision (NASDAQ: RVSN) announced that its ordinary shares have begun trading on the Frankfurt Stock Exchange under the symbol C80, while continuing to trade on the Nasdaq Capital Market under RVSN. The company said the dual listing is expected to enhance visibility and trading liquidity in Europe, broaden its investor base and provide expanded access […]

HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward […]

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 […]

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral […]

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) announced it has executed a memorandum of understanding dated March 16, 2026 with Vulcan Elements Inc. to collaborate on developing a domestic rare earth magnet supply chain for defense and commercial applications, with plans for Ucore to supply NdPr oxide and Dy oxides at commercial scale beginning in […]

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors […]

Soligenix (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while […]

ParaZero Technologies (NASDAQ: PRZO) announced it has entered into a definitive agreement for a registered direct offering with a single institutional investor expected to generate approximately $4 million in gross proceeds through the sale of 5,333,333 ordinary shares (or pre-funded warrants) at $0.75 per share. The company said proceeds will be used for general corporate purposes and […]

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026, ahead of the American Academy of Dermatology Annual Meeting. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor(R), […]